- Investing.com
Metrics to compare | PTN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −1.3x | −0.4x | |
PEG Ratio | −0.02 | −0.05 | 0.00 | |
Price/Book | 1.2x | 1.7x | 2.6x | |
Price / LTM Sales | 1.0x | 7.2x | 3.0x | |
Upside (Analyst Target) | - | 147.9% | 56.0% | |
Fair Value Upside | Unlock | 17.3% | 9.1% | Unlock |
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.